Moleculin Biotech Inc expected to post a loss of 36 cents a share - Earnings Preview

Moleculin Biotech

01/08/2025 14:49

Moleculin Biotech Inc MBRX.OQ MBRX.O is expected to  show no change in quarterly revenue when it reports  results on August 4 (estimated) for the period ending June 30 2025

​LSEG's mean analyst estimate for Moleculin Biotech Inc is for a loss of 36 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Moleculin Biotech Inc is $4.00, about 84.3% above its last closing price of $0.63

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-0.53
-0.55
-0.69
Missed
-24.3
Dec. 31 2025
-1.33
-1.28
-0.37
Beat
70.9
Sep. 30 2024
-2.44
-2.44
-2.85
Missed
-16.8​
Jun. 30 2024
-2.43
-2.51
-1.70
Beat
32.3
​​Mar. 31 2024
-3.54
-3.53
-2.02
Beat
42.8
Dec. 31 2023
-2.96
-3.05
-5.02
Missed
-64.6​
Sep. 30 2023
-3.51
-3.55
-2.85
Beat
19.7
Jun. 30 2023
-4.10
-4.10
-3.00
Beat
26.8

This summary was machine generated August 1 at 13:49 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)